Festus Ndukwu, MD
Pulmonary Disease · Joplin, MONPI 1154543999
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.2% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Shire North American Group Inc at 34.2% of the total. Reporting peaked in 2019 at $178 and has fallen 85.8% since, to $25 in 2025. That places this record below the midpoint for pulmonary disease clinicians in MO, where the typical reported total is $1,482.
Across 11 payments — averaging $24.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shire North American Group Inc$90
- Apria Healthcare LLC$44
- Actelion Pharmaceuticals US, Inc.$38
- CSL Behring$26
- Philips North America LLC$25
- Gilead$24
- plus $17 from 1 others
What the payments were for
- Food & beverage$23890%
- Education$2610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shire North American Group Inc | 1 | $90 |
| Apria Healthcare LLC | 2 | $44 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| CSL Behring | 2 | $26 |
| Philips North America LLC | 1 | $25 |
| Gilead | 2 | $24 |
| Novartis | 1 | $17 |
How this compares
$264 in reported general payments places this provider in the 25th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $58,111 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $14,563 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $8,252 |
| Sildenafil Citrate | 42 | $8,179 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $7,815 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $6,901 |
| Ventolin HfaAlbuterol Sulfate | 41 | $2,253 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $2,025 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $170 |
| Prednisone | 35 | $148 |
| Montelukast Sodium | 20 | $57 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Joplin
- Grant PiersonJoplin$138K
- Navid ZaidiJoplin$25K
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Munaf SiyamwalaIndependence$413K
- Edward CharbekSaint Louis$372K
- Adeel KhanWashington$316K
- Marin KollefSaint Louis$264K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.